Paper Details

  1. Home
  2. Paper Details

Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.

Author: BoscoloElisa, BrichtaLars, CaiYuqi, GoinesJillian, LaneAdam, Le CrasTimothy D, LiXian, PasturaPatricia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Venous malformations (VMs) are vascular disorders characterized by enlarged and tortuous veins. Most VMs are linked to a mutation in the TIE2 gene, leading to excessive vessel growth. This study discovered that combining the ABL kinase inhibitor ponatinib with rapamycin, a drug used to treat other vascular disorders, effectively regressed VMs in a mouse model. The combination therapy led to reduced cell proliferation, increased cell apoptosis, and regression of vascular channels, suggesting a promising new treatment option for VMs.
Paper Details　
Original Abstract of the Article :
Objective- Venous malformations (VMs) arise from developmental defects of the vasculature and are characterized by massively enlarged and tortuous venous channels. VMs grow commensurately leading to deformity, obstruction of vital structures, bleeding, and pain. Most VMs are associated with the acti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/30626204

データ提供：米国国立医学図書館（NLM）

Ponatinib and Rapamycin: A New Oasis in the Desert of Venous Malformations

Venous malformations (VMs), abnormal clusters of blood vessels, can cause a range of symptoms, from pain and swelling to bleeding and disfigurement. This research ventures into the desert of VM treatment, exploring the potential of a combination therapy involving ponatinib, an ABL kinase inhibitor, and rapamycin, a mammalian target of rapamycin inhibitor. The study, using a murine VM model, found that this combination therapy effectively regressed VM, offering a promising new approach to treating this challenging condition.

A New Frontier in VM Treatment: Ponatinib and Rapamycin

This study demonstrates the potential of combining ponatinib and rapamycin for the treatment of VM. The results, obtained from a murine VM model, show that this combination therapy was effective in regressing VM, suggesting a promising new approach to managing this condition. This is like discovering a new oasis in the vast desert of VM treatment, providing a source of healing and restoration.

Targeting Multiple Pathways for Effective VM Regression

This study highlights the importance of targeting multiple pathways for effective VM regression. The combination therapy of ponatinib and rapamycin, by inhibiting ABL kinase and mTOR, respectively, appears to exert a synergistic effect, leading to significant VM regression. This is like using a multi-pronged approach to irrigate a desert (VM), ensuring the survival and growth of new life (healthy tissues).

Dr.Camel's Conclusion

This study presents a compelling case for a novel combination therapy involving ponatinib and rapamycin for the treatment of VM. The findings suggest that this therapy may offer a promising new approach to managing this challenging condition, potentially leading to improved outcomes for patients with VM.

Date :
  1. Date Completed 2020-01-13
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

30626204

DOI: Digital Object Identifier

NIHMS1517842

Related Literature

Article Analysis
・Side Effects of ponatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.